Tetraphase Pharma (NASDAQ: TTPH) announced that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Trading Halts

Nomura Securities Downgrades Tetraphase Pharmaceuticals (TTPH) to NeutralSeptember 9, 2015 8:06 AM Stifel Downgrades Tetraphase Pharmaceuticals (TTPH) to HoldSeptember 9, 2015 8:01 AM SunTrust Downgrades Tetraphase Pharmaceuticals (TTPH) to NeutralSeptember 9, 2015 8:00 AM Guggenheim Cuts Price Target on Tetraphase Pharma (TTPH) Following Disappointing cUTI Data. September 9, 2015 7:57 AM Needham & Company Downgrades Tetraphase Pharmaceuticals (TTPH) to HoldSeptember 9, 2015 7:40 AM Brean Capital Downgrades Tetraphase Pharmaceuticals (TTPH) to HoldSeptember 9, 2015 7:32 AM Baird Downgrades Tetraphase Pharmaceuticals (TTPH) to NeutralSeptember 9, 2015 7:30 AM Wedbush Downgrades Tetraphase Pharmaceuticals (TTPH) to NeutralSeptember 9, 2015 7:20 AM UPDATE: Cantor Fitzgerald Downgrades Tetraphase Pharmaceuticals (TTPH) to HoldSeptember 9, 2015 7:11 AM Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTISeptember 8, 2015 4:01 PM Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTISeptember 8, 2015 4:01 PM Tetraphase Pharma (TTPH) halted with news pendingSeptember 8, 2015 4:01 PM